Trastuzumab and chemotherapy in advanced breast cancer after the failure of one earlier combination

 

While there is some evidence from retrospective trials reporting a benefit from continued trastuzumab treatment beyond disease progression, a discontinuation after disease progression is still standard of care.

Though our study is limited by the small number of patients included, we are able to strengthen this evidence. The reported decline in response rates from 42.6% in first line treatment to 30% in beyond second line compares to the expected drop of response rates with every further line of chemotherapy or endocrine therapy in palliative treatment. Stable disease and objective response combined, clinical benefit rates were 85.2% in first line, 68.5% in second line and 58.3% in beyond second line. As some other groups, we believe this to be the more significant parameter in judging the efficacy of palliative treatment, as a stabilisation of the disease without excessive toxicity often appears more important than objective remission. The high clinical benefit rate of nearly 60% even beyond second line must be seen as a clear sign of a benefit that most patients gain from treatment continuation.

Of special interest is the fact, that we did not find a statistical significant difference in time to tumour progression (TTP) between first line, second line and beyond second line trastuzumab based combinations. Although we rather expected to observe a shortening of time to disease progression with every further line of therapy, we believe this to be another sign of a potential benefit from continued combination treatment. As median overall survival was not yet reached, we are sure that our survival data will be well beyond the median 25.4 months presented in the trastuzumab pivotal trial. These results are intriguing and somewhat unexpected, but still the necessity for larger, especially randomised, trials remains.

 

Bartsch R et al.: "Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study", BMC Cancer. 2006 Mar 15;6(1):63 [Epub ahead of print]

 

Rupert Bartsch

Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria